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Abstract
Multidrug resistance (MDR) presents a major obstacle
for the successful chemotherapy of cancer. Its emer-
gence during chemotherapy is attributed to a selective
process, which gives a growth advantage to MDR cells
within the genetically unstable neoplastic cell popula-
tion. The pleiotropic nature of clinical MDR poses a
great difficulty for the development of treatment
strategies that aim at blocking MDR at the tumor cell
level. Targeting treatment to the nonmalignant vascular
network—the lifeline of the tumor—is a promising
alternative for the treatment of drug-resistant tumors.
Thepresent studydemonstrates thatMDR in cancer can
be successfully circumvented by photodynamic ther-
apy (PDT) using an antivascular treatment protocol.
We show that, although P-glycoprotein-expressing
human HT29/MDR colon carcinoma cells in culture are
resistant to PDT with Pd-bacteriopheophorbide (TOO-
KAD), the same treatment induces tumor necrosis with
equal efficacy (88% vs 82%) in HT29/MDR-derived
xenografts and their wild type counterparts, respec-
tively. These results are ascribed to the rapid antivas-
cular effects of the treatment, supporting the
hypothesis that MDR tumors can be successfully
eradicated by indirect approaches that bypass their
inherent drug resistance. We suggest that with pro-
gress in ongoing clinical trials, TOOKAD–PDT may
offer a novel option for local treatment of MDR tumors.
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Introduction
Resistance to chemotherapy with structurally and function-
ally unrelated drugs is attributed to a selection process that
originates from the genetic instability of cancer cell popula-
tions—the primary target of treatment—along with the
selection pressure applied by chemotherapeutic agents
[1]. Clinical studies have shown that multidrug resistance
(MDR) is often associated with poor patient prognosis,
underscoring the urgency for overcoming this problem [2].
The ultimate objective of MDR research is to improve
treatment outcome by developing strategies that prevent
the emergence or circumvent existing MDR [3]. However,
the classic approaches that inhibit drug efflux mediated by
various adenosine triphosphate (ATP)–dependent MDR
transporters, such as P-glycoprotein (Pgp) and others [4], were
so far unsuccessful. Themain complications in these strategies
are: 1) pharmacokinetic interactions between the MDR inhibitor
and the anticancer drug; 2) inhibition of the same transport
systems in healthy tissues, causing multiple adverse effects
[3]; and 3) failure to overcome MDR by focusing on a specific
pathway due to the multifactorial nature of clinical resistance
[2]. This situation strengthens the necessity of developing new
strategies that do not target the malignant cells directly, but
rather aim at destroying nonmalignant tumor components that
are crucial for tumor survival and development. A key system
for such an indirect targeting is tumor vasculature, which is
critical for maintaining tumor growth and development. In
addition, endothelial cells are genetically stable and unlikely
to develop MDR [5]. Antiangiogenic [1,6] and antivascular [5]
cancer therapies are examples for strategies that target the
blood vessels, and thus may provide a bypass for MDR.
Several antiangiogenic agents, mostly inhibitors of vascular
endothelial growth factor (VEGF), are now under extensive
investigation as anticancer agents [7]. There is also a clinical
report about the treatment of refractory multiple myeloma
patients with thalidomide, in which response to treatment is
attributed to an antiangiogenic mechanism [8]. The exact
mechanism of anticancer activity of thalidomide is still unclear
and may be contributed, for example, by immunomodulation. In
contrast to antiangiogenic therapy that prevents neovasculari-
zation, antivascular chemotherapy [9] or photodynamic therapy
(PDT) performed with high sensitizer concentration in the
circulation [10,11] targets existing tumor blood vessels, leading
to their occlusion with subsequent hypoxia, necrosis, and
consequent tumor destruction [5].
PDT is a binary treatment modality consisting of systemic
administration of a nontoxic substance—the photosensitizer
(drug)—and local illumination of the target tumor at a wave-
length that matches the sensitizer absorption maximum. Upon
photosensitization, the molecule is excited and, by energy
transfer to oxygen or by free radical-forming mechanisms,
generates cytotoxic singlet oxygen and/or other highly reactive
oxygen species (ROS) within the tumor. Such ROS react
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rapidly with vital cellular components (such as membranes,
cytoskeleton, and DNA), causing cellular damage and death
[12]. One of the advantages of PDT is the ability to selectively
deliver local treatment, thus avoiding injury of healthy tis-
sues, which is the greatest problem of conventional chemo-
therapies and radiotherapies.
We have synthesized a novel family of photosensitizers,
derived from the photosynthetic pigment bacteriochlorophyll
[13,14], notably Pd-bacteriopheophorbide (TOOKAD) [14],
presently found in clinical trials for prostate cancer therapy
in collaboration with Steba Biotech (Toussus Le-Noble,
France). In comparison with most clinically used photosensi-
tizers, the bacteriochlorophyll-based photosensitizers, in-
cluding TOOKAD, exhibit advantageous photochemical
and pharmacological characteristics, namely: 1) high extinc-
tion coefficient in the near-infrared (IR) (e0f10
5 at 763 nm),
enabling treatment of bulky tumors to a depth of 2 cm
[10,13,15]; and 2) rapid clearance from the circulation
(T0.5=0.6 minute) and skin (no phototoxicity at times >1 hour
after treatment; Koudinova et al., 2002, unpublished), which
minimizes skin phototoxicity. In addition, the PDT treatment
protocol where the sensitizer and the light are simultaneously
administered was shown in our laboratory to be an antivas-
cular modality that selectively induces tumor blood vessel
occlusion and stasis within minutes of illumination [16,17].
This protocol leads to the development of local ischemia,
culminating with necrosis (24–48 hours) and ultimate tumor
eradication (weeks) [10,11,15,18].
In the present study, we demonstrate that although hu-
man HT29/MDR colon carcinoma cells are resistant to
TOOKAD–PDT in culture, the same treatment has equal
efficacy when applied to the respective MDR xenografts and
their wild type (WT) counterparts. This proof of concept
suggests that by targeting the tumor vasculature, cancer
therapies such as TOOKAD–PDT can overcome MDR and
provide effective treatment for these malignancies.
Materials and Methods
Cultured Cells
Human isogenic HT29/WT and MDR cells were
obtained from Prof. I. Z. Cabantchik (Hebrew University
of Jerusalem) and cultured at 37jC in a humidified atmo-
sphere containing 8% CO2. The MDR cells were main-
tained in the presence of 300 ng/ml colchicine [19], which
was washed from the cultured MDR cells 24 hours before
the experiments.
Animals
Male CD1 nudemice (28–32 g) were housed in TheWeiz-
mann Institute animal facility and all experimental proce-
dures were conducted according to institute guidelines (1996).
Tumor Model
HumanWT andMDRHT29 cell monolayers were scraped
in saline, washed, resuspended in saline, and injected sub-
cutaneously (4–6  106 cells/0.07 ml per mouse) into the
back of themice. Tumors reached a treatment size (6–8mm)
within 2 (WT) and 4–5 (MDR) weeks. Mice bearing tumors
(z15 mm) were euthanized by anesthetic overdose.
Light Sources
Light source 1 A-home built 250-W halogen lamp focused
through a 4-cm water filter fitted with a cutoff filter (k<650 nm)
was used for in vitro studies.
Light source 2: A 763-nm diode laser (1 W; CERAMOPTEC,
Bonn, Germany) was used for in vivo studies.
Photosensitizer
In vitro studies TOOKAD, synthesized in our laboratory
[14], was dissolved in ethanol immediately before use and
further diluted to the final concentration in culture medium
containing 1% ethanol.
In vivo studies TOOKAD (2.5 mg/ml) was administered in
5% Cremophor El–based formulation (NEGMA-LERADS,
Toussus-Le-Noble, France).
PDT Protocol
In vitro studies Cells (4–6  104 per well) were plated in
96-well plates and cultured for 24 hours. The cells were then
preincubated in the dark (4 hours) with the indicated TOO-
KAD concentrations, washed with fresh medium, and illumi-
nated from below at a dose of 12 J/cm2. After illumination, the
cells were placed in the culture incubator and cell survival was
determined after 24 hours using the neutral red viability
assay.
In vivo studies Mice, anesthesized by intraperitoneal in-
jection of 40 ml of a mixture of ketamine (Rhone Merieux,
Lyon, France) and xylazine 2% (Vitamed, Hedera, Israel)
(85:15 vol:vol), were injected intravenously with 10 mg/kg
TOOKAD, and the tumor was immediately illuminated (field
U=14 mm) at a dose of 90 J/cm2. Tumor response (using
local necrosis on day 8 post-PDT as an endpoint) was
photographically recorded and tumor volume was
assessed [20].
Controls Dark control—cells or mice treated with TOOKAD
but not illuminated. Light control—cells illuminated without
incubation with TOOKAD, or mice intravenously injected with
vehicle and illuminated. Untreated control—no light or drug
(served as 100% cell survival for in vitro studies).
Histology
Tumors were excised from sacrificed animals, fixed in 4%
formaldehyde in phosphate-buffered saline (PBS) at room
temperature (RT; 48 hours), and paraffin-embedded. Sec-
tions were prepared and stained with hematoxylin/eosin
(HNE) using standard protocols.
Immunohistochemistry
Cultured cells Cells were grown on coverslips (48 hours),
washed with PBS, and briefly fixed (5 minutes, 2% para-
formaldehyde at 4jC). Samples were then blocked
(1 hour, 2% BSA, and 20% horse serum in PBS at RT).
Cells were stained for Pgp by overnight incubation with 20
mg/ml monoclonal anti-human Pgp antibodies (4E3; Dako,
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Carpinteria, CA) at 4jC, followed by treatment with alkaline
phosphatase (AP)–conjugated goat anti-mouse antibodies
(Promega, Madison, WI) using fast red (Sigma, St. Louis,
MO) as a color substrate.
Tumor sections Paraffin-embedded sections were depar-
affinized with xylene and rehydrated by serial 5-minute
incubations in 100%, 95%, and 70% ethanol and water.
Endogenous peroxidases were inactivated by incubation in
3% H2O2 (Merck, Darmstadt, Germany), followed by block-
ing with 1% bovine serum albumin (BSA; Sigma) and 2%
goat serum in PBS. Sections were incubated overnight
(4jC) with 20 mg/ml 4E3 Pgp, or with polyclonal anti-HNE
antibodies (1:500; Calbiochem, San Diego, CA). Sections
were then treated (1 hour at RT) with goat anti-mouse or
goat anti-rabbit peroxidase-conjugated antibodies (Jack-
son, ME) using 3-amino-9-ethylcarbazole (AEC; Sigma)
as color substrate.
Cells and sections were counterstained with 0.1% hema-
toxylin (Sigma). In the negative control, the primary anti-
bodies were omitted. All intermediate washes were
performed with PBS.
Light microscopy was performed using a microscope
(Nikon Optiphot 2; Nikon, Tokyo, Japan) equipped with a
digital camera (DVC Company, Austin, TX).
Preparation of Cell and Tissue Extracts
Cell lysates Cells were washed twice with cold PBS,
scraped in RIPA [20 mM Tris–HCl, 137 mM NaCl, 10%
glycerol, 0.1% sodium dodecyl sulfate (SDS), 0.5% deoxy-
cholate, 1% Triton X-100, 2 mM EDTA, pH 8.0, 1 mM PMSF,
20 mM leupeptin], sonicated for 10 seconds, centrifuged at
2  104g (15 minutes), and stored at 20jC until use. All
steps were carried out on ice.
Tumor extracts Tumors were homogenized in RIPA.
Homogenates were kept at 4jC (15 minutes) and centrifuged
at 2  104g (10 minutes). The supernatant was collected
and stored at 20jC until use.
Figure 1. Resistance of human HT29/MDR cells to TOOKAD-PDT. (A) Cells
were preincubated in the dark with TOOKAD, washed, and illuminated.
Closed circles, WT/dark; open circles, WT/PDT; closed squares, MDR/dark;
open squares, MDR/PDT. The graphs represent the mean±SE of four
independent experiments performed in triplicates. Cell survival is presented
as a percentage of untreated control. *No significant difference between
values (MDR/dark and MDR/PDT) by Fisher’s LSD test. (B and C)
Immunostaining for Pgp of cultured HT29 MDR and WT cells, respectively.
(B, inset) Immunoblot of the respective cell lysates with anti-Pgp antibodies.
Bands representing a-tubulin (55 kDa) and Pgp (170 kDa) are shown. (D)
TOOKAD-PDT of HT29/MDR cells in the absence (closed squares, dark/
VP; open squares, PDT/VP) or presence (closed triangles, dark/VP+;
open triangles, PDT/VP+) of 50 M VP. Cells were preincubated with VP for
30 minutes prior to the standard PDT protocol. The curves represent the
mean±SE of three independent experiments performed in triplicates. Cell
survival is presented as percent of untreated control.
Figure 2. Response of HT29 MDR and WT xenografts to TOOKAD-PDT. (A and B) Pgp immunostaining of MDR and WT xenografts. (B, inset) Immunoblot of
respective tumor homogenates with anti –Pgp antibodies. Tubulin (55 kDa) and Pgp (170 kDa). (C and D) Tumors before and (E and F) 8 days after PDT. (G and
H) Tumor growth curves starting from day of treatment (day 0). Diamonds, PDT; squares, light control; triangles, dark control; circles, untreated control. The
number of mice per group was as follows: PDT (WT and MDR, n=17 each), dark control (WT and MDR, n=6 each), untreated (WT and MDR, n=4 each), and light
control (WT, n=8 and MDR, n=5). Bars represent mean±SE.
Antivascular Therapy of Multidrug-Resistant Tumors Preise et al. 477
Neoplasia . Vol. 5, No. 6, 2003
Sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) and Immunoblot Analysis
Proteins (30–100 mg protein per lane) were separated on
7.5% SDS-PAGE and blotted onto nitrocellulose mem-
branes. Membranes were blocked with 10% milk and 1%
goat serum in PBS. Pgp was identified using monoclonal
anti-human Pgp antibodies (C219, 1:500; Alexis Biochem,
Montreal, Canada) and peroxidase-conjugated or AP-
conjugated goat anti-mouse IgG as secondary antibod-
ies. Bands were visualized using ECL (Santa Cruz Bio-
technology, Santa Cruz, CA) or incubation with fast red,
respectively. a-Tubulin was detected with monoclonal
anti-a-tubulin antibodies (Sigma).
Results
Cultured HT29/MDR Cells Are Resistant to TOOKAD–PDT
To demonstrate that the MDR phenotype renders HT29/
MDR cells resistant to the direct effects of TOOKAD–PDT,
we subjected cultured HT29/WT and MDR cells to
TOOKAD–PDT in vitro. The WT cells responded to PDT
in a TOOKAD concentra t ion-dependent manner
(LD50=0.3 mM), whereas no response was seen in the
absence of light (dark control) (Figure 1A). In contrast, the
MDR cells did not respond to PDT under the same experi-
mental conditions (LD50 >> 5 mM) (the apparent decrease in
cell survival in the MDR/PDT group was statistically insignif-
icant (P = .5) by two-way analysis of variance (ANOVA).
The Pgp drug transporter is overexpressed in MDR cells
[21]. To verify the presence of this marker in the HT29/MDR
variants, we subjected cells to immunostaining, and cell
lysates to SDS-PAGE and immunoblotting using monoclonal
anti–Pgp antibodies. As expected, Pgp staining was ob-
served in the MDR (Figure 1B, inset) but not in WT cells
(Figure 1C). It was thus presumed that if the resistance to
TOOKAD–PDT is indeed Pgp-dependent, then preincuba-
tion of the MDR cells with verapamil (VP), a known inhibitor
of Pgp [22], should sensitize them to the cytotoxic treatment.
Indeed, we found that VP-pretreated HT29/MDR cells
responded to TOOKAD–PDT (Figure 1D), specifically con-
firming the role of the Pgp efflux pump in the resistance of
these cultured MDR cells to TOOKAD–PDT.
MDR HT29 Xenografts Are Sensitive to PDT with TOOKAD
It was hypothesized that although MDR cells are resis-
tant to PDT in vitro, they should be susceptible to TOO-
KAD–PDT-mediated ablation of blood vessels in vivo. To
test this idea, we subcutaneously implanted MDR or WT
HT29 cells in mice and examined the effect of TOOKAD–
PDT on the tumors in vivo. To verify the maintenance of the
MDR phenotype in the xenografts, we examined Pgp
expression by immunohistochemical analysis of tumor sec-
tions (Figure 2, A and B) and by immunoblotting of tumor
homogenates using anti-Pgp antibodies (Figure 2B, inset).
Only tumors derived from MDR cells showed positive
staining for Pgp, whereas the WT tumors were negative,
illustrating that the MDR phenotype was indeed maintained
in vivo. Tumors that reached treatment size (Figure 2, C
and D) were subjected to TOOKAD–PDT and the response
to treatment was monitored by clinical and histopathological
means. Both variants responded positively, as judged by
necrosis on day 8 post-PDT (Figure 2, E and F). Further
follow-up of tumor size showed growth inhibition of both WT
and MDR tumors by PDT (Figure 2, G and H). In contrast,
tumors in the control groups continued to grow (Figure 2, G
and H) Furthermore, the observed efficacy of treatment on
the MDR (88.2%) and WT (82.4%) tumors was almost
identical (Table 1). When also considering animals with
incomplete response (necrosis covering only part of the
tumor), these results amount to (16/17, 94.1%) and (17/17,
Table 1. The Response of Human HT29 WT and MDR Xenografts to PDT
with TOOKAD.
Tumor Type Number of Animals Response (Necrosis on Day 8)
Complete Partial
MDR 17 15 (88.2%) 1 (5.9%)
WT 17 14 (82.3%) 3 (17.6%)
Figure 3. Histological sections of MDR and WT xenografts. (A and B) HNE staining before and (C and D) 24 hours after PDT. (E and F) HNE immunostaining
before and (G and H) 24 hours after PDT. Bars=50 m.
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100%) respectively. Histopathological examination of both
xenograft variants in comparison with untreated controls
showed degenerative changes in the entire neoplastic
population with clear-cut necrosis, including pyknosis and
karyolysis in about 30–40% of the cells, 24 hours post-
PDT [Figure 3, A and B (before PDT); Figure 3, C and D
(24 hours after PDT)]. There were edema and mixed
inflammatory infiltration in the surrounding tissues. Blood
vessels were dilated and scattered necrotic debris was
visible in the vicinity and within the walls of some dermal
and subcutaneous vessels, away from the tumor together
with extensive hemorrhage observed in both tumor types.
One of the common features of PDT-induced damage
is local lipid peroxidation (LPO), which can be assessed
immunohistochemically using 4-hydroxy-2-nonenal (HNE)
as marker [10]. Analysis of PDT-induced LPO indicates
that the degree of photodamage was similar in both tumor
variants (Figure 3, E–H). Thus, both clinically and histo-
pathologically, MDR and WT tumors responded similarly to
PDT. The response of the MDR tumor variant to TOO-
KAD–PDT is therefore consistent with the antivascular
activity of this treatment, which targets the nonmalignant
host blood vessels—the only common denominator of the
two tumor variants.
Discussion
In this study, we hypothesized that the inherent resistance
of HT29/MDR cells to PDT with TOOKAD can be effectively
circumvented when the respective xenografts are treated
with antivascular treatment protocol. To prove this point in a
controlled manner, we first demonstrated that in culture,
HT29/MDR cells exhibit resistance to TOOKAD–PDT,
whereas the respective WT cells are fully responsive
(Figure 1A). We secondly grafted the same cells to CD1
nude mice and demonstrated that TOOKAD–PDT induces
necrosis in xenografts derived from resistant HT29/MDR
and isogenic WT counterparts with equal efficacy (Figure 2
and Table 1). Pgp expression was positively correlated with
the MDR phenotype of the cultured MDR cells (Figure 1B)
and with resistance to TOOKAD–PDT (Figure 1A), which
was abolished by the inhibition of TOOKAD efflux by VP
(Figure 1D). However, Pgp expression in vivo (Figure 2, E
and B, inset) did not correlate with the tumor phenotype,
where the MDR tumors responded well to TOOKAD–PDT
(Figure 2, E and G; Figure 3, C and G). This finding is
consistent with the notion that the PDT protocol used here
does not target the tumor cells, but rather the host-derived
vasculature, which is identical in both tumors. PDT with
TOOKAD, like its predecessor bacteriochlorophyll serine
[11], was shown to eradicate solid tumors by vascular
destruction and blood stasis [16,17].
Furthermore, we previously showed that the antitumor
activity of TOOKAD–PDT is secondary to the photodynamic
induction of local hypoxia and necrosis [10] and is likely to be
independent of the tumor type. In contrast to TOOKAD, most
other photosensitizers used in experimental and clinical
cancer therapies were designed to selectively accumulate
in and destroy the malignant cells and tumors upon illumina-
tion [23]. It is, therefore, not surprising that under culture
conditions, PDT with sensitizers, such as Photofrin or copper
benzochlorin iminium salt (CuBI), is generally [24,25],
although not always [26], ineffective against MDR cells but
effective against their parental WT variants, as is the case
with TOOKAD. Although other sensitizers (Foscan, hyper-
icine) were shown to exert vascular effects in animal models,
the ability of this effect by itself to induce complete tumor
eradication was not conclusive [27,28]. Verteporfin, however,
is an agent designed as a specific antivascular modality and
was introduced for treatment of age-related macular degen-
eration [29]. However, PDT with hydrophilic sensitizers such
asmonocationic porphyrin (MCP) and 5-aminolaevulinic acid
(5-ALA) was found to be cytotoxic for both Pgp-expressing
MDR and their parental WT variants in culture [30,31]. The
sensitivity of MDR cells to these agents is thought to be
because they are not recognized by Pgp. In agreement with
these findings, the charged aluminum disulfonated phthalo-
cyanine (AlS2Pc) was found to be effective against MDR and
WT murine tumors [32], yet no specific mechanism was
indicated. It appears that the response to PDT with classic
sensitizers may vary with tumor type, the nature of the
sensitizer, and the specific MDR mechanism involved, limit-
ing their use in the treatment of MDR tumors. In contrast,
antivascular PDT with TOOKAD is predicted to be indepen-
dent of tumor type and MDR mechanism. To the best of
our knowledge, however, no controlled in vivo studies with
clinically relevant photosensitizers reported successful treat-
ment of MDR tumors. One can anticipate that the above-
mentioned PDT agents bearing antivascular activity will
behave similarly to TOOKAD in the treatment of MDR tumors
depending on: 1) whether their sole antivascular action is
sufficient to cause tumor eradication, as is the case for
TOOKAD; and 2) if the respective MDR cells in culture are
resistant to their photodynamic activity. The emergence of
drug resistance in tumor therapy is a likely consequence of
selection pressure promoted by chemotherapeutic drugs on
the neoplastic component of the tumor, typically character-
ized by high mutation rates and genetic instability. In an
attempt to develop strategies that circumvent this therapeutic
risk, it was logical to approach the tumor indirectly by target-
ing its blood supply. Tumor-associated endothelial cells are
nonmalignant and, as such, are less likely to develop resis-
tance [1]. Their selective targeting by TOOKAD–PDT was,
therefore, expected to succeed in cases where conventional
cancer therapies failed.
Thus, results presented here support the hypothesis that
by targeting the tumor vasculature, TOOKAD–PDT circum-
vents drug resistance of malignant tumor cells, permitting
effective treatment of MDR tumors. Moreover, we presume
that the brief, single, 10-minute PDT protocol itself is not
likely to induce drug resistance.
In summary, this study suggests a new, promising strat-
egy for effective treatment of drug-resistant tumors, based
on targeting of the tumor blood vessels by TOOKAD–PDT.
We hope that with progress in ongoing clinical trials, TOO-
KAD–PDT will also improve the treatment outcome for
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patients with MDR tumors and enable cancer treatment
where conventional chemotherapy fails.
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